STARPHARMA HOLDINGS LIMITED |
Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
| 0.135 AUD | 0.00% |
|
+3.85% | -20.59% |
| 04-08 | Starpharma, Medicxi Co-Found Petalion Therapeutics; Shares Surge 16% | MT |
| 03-18 | Starpharma Holdings Limited(ASX:SPL) dropped from S&P/ASX Emerging Companies Index | CI |
| Sales 2022 | 5.16M 3.37M 270M | Sales 2023 | 4.21M 2.75M 220M | Capitalization | 127M 83.12M 6.65B |
|---|---|---|---|---|---|
| Net income 2022 | -16M -10.45M -837M | Net income 2023 | -15M -9.8M -784M | EV / Sales 2022 | 50.5 x |
| Net cash position 2022 | 41.73M 27.26M 2.18B | Net cash position 2023 | 26.91M 17.58M 1.41B | EV / Sales 2023 | 23.8 x |
| P/E ratio 2022 |
-18.5
x | P/E ratio 2023 |
-7.75
x | Employees | - |
| Yield 2022 * |
-
| Yield 2023 |
-
| Free-Float | 92.68% |
More Fundamentals
* Assessed data
More news
More press releases
| 1 week | +3.85% | ||
| Current month | +8.00% | ||
| 1 month | +3.85% | ||
| 3 months | -6.90% | ||
| 6 months | -3.57% | ||
| Current year | -20.59% |
1 week
0.13
0.14
1 month
0.120.15
Current year
0.120.19
1 year
0.120.51
3 years
0.121.93
5 years
0.122.52
10 years
0.122.52
| Managers | Title | Age | Since |
|---|---|---|---|
Cheryl Maley
CEO | Chief Executive Officer | - | 01-07 |
Justin Cahill
DFI | Director of Finance/CFO | - | 02/04/23 |
Tony Eglezos
PRN | Corporate Officer/Principal | - | 11/08/13 |
| Members of the board | Title | Age | Since |
|---|---|---|---|
Jeff Davies
BRD | Director/Board Member | - | 31/03/22 |
Robert Thomas
CHM | Chairman | 79 | 03/12/13 |
David McIntyre
BRD | Director/Board Member | 53 | 29/02/20 |
| Date | Price | Change | Volume |
|---|---|---|---|
| 26/04/24 | 0.135 | 0.00% | 139,014 |
| 24/04/24 | 0.135 | +8.00% | 115,702 |
| 23/04/24 | 0.125 | -3.85% | 279,417 |
| 22/04/24 | 0.13 | 0.00% | 547,549 |
| 19/04/24 | 0.13 | +4.00% | 313,928 |
Delayed Quote Australian S.E., April 26, 2024 at 07:10 am
More quotes
Starpharma Holdings Limited is an Australia-based biopharmaceutical company. The principal activities of the Company consist of research, development and commercialization of dendrimer products for pharmaceutical, life-science and other applications. It is focused on developing and commercializing novel therapeutic products that address global healthcare needs. The Company is also involved in the development of nano-scale materials, including the development of VivaGel for the management and prevention of bacterial vaginosis, and as an antiviral condom coating, and VIRALEZE, an antiviral nasal spray. The Company is also applying its proprietary dendrimers to drug delivery to create improved pharmaceuticals and has developed the valuable DEP delivery platform. VIRALEZE is a broad-spectrum nasal spray intended to provide a moisturizing and protective barrier in the nose that traps and blocks cold/respiratory viruses. It also offers VivaGel BV and VivaGel Condom products.
Sector
Pharmaceuticals
Calendar
20/08/2024
- Q4 2024 Earnings Release (Projected)
Annual profits - Rate of surprise
| 1st Jan change | Capi. | |
|---|---|---|
| -20.59% | 36.28M | |
| +25.83% | 661B | |
| +27.00% | 566B | |
| -6.76% | 352B | |
| +20.34% | 332B | |
| +3.00% | 283B | |
| +13.09% | 231B | |
| +5.46% | 200B | |
| -9.61% | 195B | |
| -6.26% | 145B |
- Stock Market
- Equities
- SPL Stock
